# An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer

> **NCT01266954** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** GSK2141795

## Key facts

- **NCT ID:** NCT01266954
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-01
- **Primary completion:** 2011-09-01
- **Final completion:** 2011-09-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266954, "An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01266954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*